Mindfulness
June 8, 2023
Jacinda K Dariotis, Keren Mabisi, Rachel Jackson-Gordon et al.
Objectives: In the context of adverse social conditions, adolescents may not progress to adulthood with the emotional and behavioral skills needed to effectively navigate inevitable life challenges. Appropriately timed, evidence-based interventions have the potential to improve youth developmental trajectories. This qualitative study explored adolescents' perceptions of two different types of...
Cureus
June 1, 2023
Aneeque Jamil, Sai Dheeraj Gutlapalli, Marya Ali et al.
46 citations
This article discusses the power of meditation and how beneficial it is for the body. Magnetic resonance imaging (MRI) has shown many positive brain changes and improved several brain functions. Meditation has several benefits improving the immune system and inflammatory processes by decreasing cytokine; appropriate telomere shortening also has helped healthy aging. Regarding physical health,...
Journal of Medical Ethics
May 30, 2023
Scott Hoener, Aaron Wolfgang, David A. Nissan et al.
6 citations
Psychedelic treatments, particularly 3,4-methylenedioxymethamphetamine (MDMA)-assisted and psilocybin-assisted therapies, have recently seen renewed interest in their clinical potential to treat various mental health conditions. Clinical trials for both MDMA-assisted and psilocybin-assisted therapies have shown to be highly efficacious for post-traumatic stress disorder and major depression....
Neuropharmacology
May 27, 2023
David J Heal, Sharon L. Smith, Sean J Belouin et al.
50 citations
This Special Issue of Neuropharmacology on psychedelics provides a timely and comprehensive update on progress following the previous Neuropharmacology Special Issue "Psychedelics: New Doors, Altered Perceptions". Remarkable advances have been made in basic and clinical research on psychedelics in the five years since 2018. It is partly based on the seminar series focused on psilocybin...
The International Journal of Neuropsychopharmacology
May 24, 2023
Yuru Nie, Ye Zhang, Rong Ren et al.
1 citation
Trauma-related nightmares (TRN) are a reexperiencing of previous traumas that happened in real life or a dream sequence initially triggered by trauma that leads to recurrent emotional dreaming about the trauma. TRN, one of the most common symptoms in posttraumatic stress disorder (PTSD), are disturbing mental experiences that generally occur during rapid eye movement (REM) sleep and often...
World Journal of Psychiatry
May 19, 2023
Lakshan N Fonseka, Benjamin K.p. Woo
12 citations
With the Food and Drug Administration designation in 2017 of 3,4-methylenedioxymethamphetamine (MDMA) as a breakthrough therapy in post-traumatic stress disorder and psilocybin in treatment-resistant depression, psychedelic drugs have continued to garner the attention of researchers and clinicians for their promise of unmatched, rapid improvement in a multitude of psychiatric conditions....
Frontiers in Psychiatry
May 18, 2023
Tigran Makunts, Diane Dahill, Lisa Jerome et al.
6 citations
3,4-Methylenedioxymethamphetamine (MDMA) is currently being investigated as an adjunctive treatment to therapy for posttraumatic stress and other anxiety related disorders in clinical trials. Within the next few years MDMA-assisted therapy is projected for approval by regulatory authorities. MDMA's primary mechanism of action includes modulation of monoamine signaling by increasing release and...
PARIPEX INDIAN JOURNAL OF RESEARCH
May 15, 2023
Chirag Ambaliya, Dimple Gupta, Ashok Vala et al.
The purpose of this review article is to give a summary of the literature on the use of psychedelic drugs, such as psilocybin, LSD, ayahuasca, and MDMA, in the treatment of various mental health conditions, such as depression, anxiety, PTSD, and substance use disorders. This review's main goal is to highlight recent human studies on the use of particular psychedelic drugs, like psilocybin, LSD,...
Australian & New Zealand Journal of Psychiatry
May 6, 2023
Julia Lappin, Shane Darke, Michael Farrell
Australian & New Zealand Journal of Psychiatry, 57(6) Interest in prescribing psychoactive drugs as treatments for mental health conditions has been highlighted recently by the decision by the Therapeutic Goods Administration (TGA) to permit, from 1 July 2023, authorised psychiatrists to prescribe medicines containing psilocybin for treatment-resistant depression and...
Sleep
May 1, 2023
Brian D. Robertson, A. Liem
Introduction: Nightmare disorder and post-traumatic stress disorder (PTSD)-associated nightmares can be treatment-resistant in many patients. There are no recommended treatments for these conditions currently. Methods: NightWare is a novel FDA-approved class II medical device which improves sleep in patients with nightmare disorder and PTSD-associated nightmares. It uses data from a smart watch...